Immunohistochemical assessment of primary breast tumors and metachronous brain metastases, with particular regard to differences in the expression of biological markers and prognosis

Omoto,Yawara; Kurosumi,Masafumi; Hozumi,Yasuo; Oba,Hanako; Kawanowa,Kaori; Takei,Hiroyuki; Yasuda,Yoshikazu

doi:10.3892/etm_00000088

Immunohistochemical assessment of primary breast tumors and metachronous brain metastases, with particular regard to differences in the expression of biological markers and prognosis

Authors:
- Yawara Omoto
- Masafumi Kurosumi
- Yasuo Hozumi
- Hanako Oba
- Kaori Kawanowa
- Hiroyuki Takei
- Yoshikazu Yasuda
View Affiliations

Affiliations: Department of Pathology, Saitama Cancer Center, Saitama 362-0806, Japan
Published online on: July 1, 2010 https://doi.org/10.3892/etm_00000088
Pages: 561-567

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In this study, we conducted an immunohistochemical analysis of primary breast tumors and metachronous brain metastases to compare the differences in the expression of biological markers between the two. Carcinoma tissues from primary breast tumors and metachronous brain metastases collected from 21 patients were examined immunohistochemically for the expression status of the estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor (HER)-2, Ki-67, bcl-2 and p53, and the results were compared. In addition, the relationships between the expression of these factors and prognosis were evaluated. There were no significant differences in the frequencies of ER-, PgR-, HER-2-, bcl-2- or p53-positivity between the primary breast tumors and metachronous brain metastases. While the Ki-67 labeling index (LI) was high in both the primary breast tumors and brain metastases, it was significantly higher in the brain metastases than in the corresponding primary breast tumors (P=0.003). With regard to the prognosis, breast cancer patients who showed ER-positivity in the primary tumors showed significantly longer survival after primary diagnosis (P=0.0076). Furthermore, breast cancer patients who exhibited ER-positivity, bcl-2-positivity or p53-negativity in the primary tumors showed significantly longer intervals from primary diagnosis to the detection of the brain metastases. Of all the markers, only the Ki-67 LI was significantly higher in the brain metastases than in the primary breast tumors. We confirmed that the tumor characteristics were worse in the metachronous brain metastases.

View Figures

View References

1.	Lin NU, Bellon JR and Winer EP: CNS metastases in breast cancer. J Clin Oncol. 22:3608–3617. 2004. View Article : Google Scholar : PubMed/NCBI
2.	Shaffrey ME, Mut M, Asher AL, Burri SH, Chahlavi A, Chang SM, Farace E, Fiveash JB, Lang FF, Lopes MB, Markert JM, Schiff D, Siomin V, Tatter SB and Voqelbaum MA: Brain metastasis. Curr Probl Surg. 41:665–741. 2004. View Article : Google Scholar
3.	Engel J, Eckel R, Aydemir U, Aydemir S, Kerr J, Schlesinger-Raab A, Dirschedl P and Holzel D: Determinants and prognoses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys. 55:1186–1195. 2003. View Article : Google Scholar : PubMed/NCBI
4.	Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ, Crowe JP, Choueiri TK, Dawson AE, Butt GT, Tubbs RR, Casey G and Weil RJ: Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol. 30:1097–1103. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Ryberg M, Nielsen D, Osterlind K, Andersen PK, Skovsgaard T and Dombernowsky P: Predictors of central nervous system metastasis in patients with metastatic breast cancer: A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast Cancer Res Treat. 91:217–225. 2005. View Article : Google Scholar : PubMed/NCBI
6.	Evans AJ, James JJ, Cornford EJ, Chan SY, Burrell HC, Pinder SE, Gutteridge E, Robertson JF, Hornbuckle J and Cheung KL: Brain metastasis from breast cancer: identification of a high-risk group. Clin Oncol. 16:345–349. 2004. View Article : Google Scholar : PubMed/NCBI
7.	Slimane K, Andre F, Delaloge S, Dunant A, Perez A, Grenier J, Massard C and Spielmann M: Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol. 15:1640–1644. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Maki D and Grossman RI: Patterns of disease spread in meta-static breast carcinoma: influence of estrogen and progesterone receptor status. AJNR Am J Neuroradiol. 21:1064–1066. 2000.PubMed/NCBI
9.	Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 133:1710–1715. 1984.PubMed/NCBI
10.	Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Bonetti A, Nortilli R, Pelosi G and Cetto GL: Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer. 74:433–437. 1997. View Article : Google Scholar : PubMed/NCBI
11.	Railo M, Lundin J, Haglund C, von Smitten K, von Boguslawsky K and Nordling S: Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol. 36:369–374. 1997. View Article : Google Scholar : PubMed/NCBI
12.	Pierga JY, Leroyer A, Viehl P, Mosseri V, Chvillard S and Magdelenat H: Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat. 37:57–64. 1996. View Article : Google Scholar : PubMed/NCBI
13.	Railo M, Nordling S, von Boguslawsky K, Leivonen M, Kyllonen L and von Smitten K: Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer. 68:579–583. 1993. View Article : Google Scholar : PubMed/NCBI
14.	Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M and Lampertico P: Proliferation index as a prognostic marker in breast cancer. Cancer. 71:3926–3931. 1993. View Article : Google Scholar : PubMed/NCBI
15.	Caly M, Genin P, Al Ghuzlan A, Elie C, Freneaux P, Klijanienko J, Rosty C, Sigal-Zafrani B, Vincent-Salomoni A, Douggaz A, Zidane M and Sastre-Garau X: Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases. Anticancer Res. 24:3283–3288. 2004.
16.	Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, Mors R, Haegele P, Eber M and Ghnassia JP: Comparative value of tumour grade hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 40:205–211. 2004. View Article : Google Scholar
17.	Bonetti A, Zaninelli M, Rodella S, Molino A, Sperotto L, Piubello Q, Bonetti F, Nortilli R, Turazza M and Cetto GL: Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma. Breast Cancer Res Treat. 38:289–297. 1996. View Article : Google Scholar : PubMed/NCBI
18.	MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, De Mascarel I and Coindre JM: Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer. 74:1458–1465. 1996. View Article : Google Scholar
19.	Aas T, Geisler S, Eide GE, Haugen DF, Varhaug JE, Bassoe AM, Thorsen T, Berntsen H, Borresen-Dale AL, Akslen LA and Lonning PE: Predictive value of tumor cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer. 39:438–446. 2003. View Article : Google Scholar : PubMed/NCBI
20.	Shabani HK, Kitange G, Tsunoda K, Anda T, Tokunaga Y, Shibata S, Kaminogo M, Hayashi T, Ayabe H and Iseki M: Immunohistochemical expression of E-cadherin in metastatic brain tumors. Brain Tumor Pathol. 20:7–12. 2003. View Article : Google Scholar : PubMed/NCBI
21.	Buxant F, Anaf V, Simon P, Favt I and Noel JC: Ki-67 immunostaining activity is higher in positive axillary lymph nodes than in the primary breast tumor. Breast Cancer Res Treat. 75:1–3. 2002. View Article : Google Scholar : PubMed/NCBI
22.	Cabibi D, Mustacchio V, Martorana A, Tripodo C, Campione M, Calascibetta A, Sanguedolce R and Aragona F: Lymph node metastases displaying lower Ki-67 immunostaining activity than the primary breast cancer. Anticancer Res. 26:4357–4360. 2006.PubMed/NCBI
23.	Lear-Kaul KC, Yoon HR, Kleinschmidt-DeMasters BK, McGavran L and Singh M: HER-2/neu status in breast cancer metastases to central nervous system. Arch Pathol Lab Med. 127:1451–1457. 2003.PubMed/NCBI
24.	Fuchs IB, Loebbecke M, Buhler H, Stoltenburg-Didinger G, Heine B, Lichtenegger W and Schaller G: HER2 in brain metastases: issues of concordance, survival, and treatment. J Clin Oncol. 20:4130–4133. 2002. View Article : Google Scholar : PubMed/NCBI
25.	Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Janicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB and Miller WR: Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 63:6523–6531. 2003.PubMed/NCBI
26.	Dunn JM, Hastrich DJ, Newcomb P, Webb JCJ, Maitland NJ and Farndon JR: Correlation between p53 mutations and antibody staining in breast carcinoma. Br J Surg. 80:1410–1412. 1993. View Article : Google Scholar : PubMed/NCBI
27.	Thompson AM, Anderson TJ, Condie A, Prosser J, Chetty U, Carter DC, Evans HJ and Steel CM: p53 allele losses, mutations and expression in breast cancer and their relationship to clinicopathological parameters. Int J Cancer. 50:528–532. 1992. View Article : Google Scholar : PubMed/NCBI
28.	Borrensen AL, Hovig E, Smith-Sorensen B, Malkin D, Lystad S, Andersen TI, Nesland JM, Isselbacher KJ and Friend SH: Constant denaturation gel electrophoresis (CDGE) as a rapid screening technique for p53 mutations. Proc Natl Acad Sci USA. 88:8405–8409. 1991. View Article : Google Scholar : PubMed/NCBI
29.	Binder C, Marx D, Overhoff R, Binder L, Schauer A and Hiddemann W: Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Ann Oncol. 6:1005–1010. 1995.PubMed/NCBI
30.	Gee JM, Robertson JF, Ellis IO, Willsher P, McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blamey RW and Nicholson RI: Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer. 59:619–628. 1994. View Article : Google Scholar